NCT06379217 2026-03-11NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.NovartisPhase 1 Active not recruiting31 enrolled
NCT05999968 2026-03-05Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentEli Lilly and CompanyPhase 1 Completed10 enrolled